Some aspects of clearance of mitoguazone in cancer patients and experimental cancer models.

Abstract

Mitoguazone (methylglyoxal-bis(guanyl-hydrazone), MGBG) was studied by its first-pass mechanism in both cancer patients and experimental cancer models. It appears from the study that 90% of MGBG is cleared from the plasma within minutes. 24-h recovery in the urine, however, did not exceed 16% so that 84% of the drug seems to be bound to subcellular compartments. Tissue levels of MGBG in the normal prostate ranged higher than in experimental prostate cancer type 3327 M/G, i.e. enhanced clearance from cancer tissues: polyamine biosynthetic enzymes ornithine decarboxylase as well as S-adenosylmethionine decarboxylase are contrarily affected by MGBG.

• Authors: U Dunzendorfer, M E Balis, W F Whitmore
• Journal: Arzneimittel-Forschung (Arzneimittelforschung) Vol. 36 Issue 3 Pg. 506-8 (Mar 1986) ISSN: 0004-4172 [Print] Germany
• PMID: 3518731 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Ornithine Decarboxylase
• Adenosylmethionine Decarboxylase
• Mitoguazone

Topics

• Adenocarcinoma (drug therapy)
• Adenosylmethionine Decarboxylase (analysis, antagonists & inhibitors)
• Animals
• Carcinoma, Renal Cell (drug therapy)
• Cell Line
• Cells, Cultured
• Clinical Trials as Topic
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Humans
• Infusions, Parenteral
• Kidney Neoplasms (drug therapy)
• Male
• Mice
• Mice, Inbred Strains
• Mitoguazone (administration & dosage, metabolism, toxicity)
• Ornithine Decarboxylase (analysis)
• Prostatic Neoplasms (drug therapy)
• Rats
• Rats, Inbred Strains
• Tissue Distribution